The Drug Enforcement Administration (DEA) and the U.S. Division of Well being & Human Providers (HHS) simply finalized their March 2023 proposed rule concerning telemedicine prescribing of buprenorphine. The last rule, efficient February 18, 2025, permits DEA‑registered practitioners to prescribe Schedule III-V managed substances, i.e., buprenorphine, to deal with opioid use dysfunction (OUD) by audio-video visits and thru audio-only visits in particular circumstances after sure necessities are met. Though these practices are at the moment allowed below the COVID-era telemedicine prescribing flexibilities by the tip of the 2025, the ultimate rule introduces extra necessities for these prescriptions.
쉬운 목차
ToggleNecessities of the Last Rule
PDMP Verify
Earlier than prescribing a Schedule III-V managed substance authorized by the U.S. Meals & Drug Administration (FDA) to deal with OUD by way of telemedicine (at the moment restricted to buprenorphine), DEA-registered practitioners should evaluation the prescription drug monitoring program (PDMP) database of the state by which the affected person is positioned on the time of the encounter.
- Scope of Evaluate: Practitioners should verify PDMP information for any managed substances issued to the affected person inside the previous 12 months. If lower than a 12 months of information is out there, practitioners should evaluation your complete accessible interval.
- Preliminary Prescription:
- After reviewing the PDMP information and documenting the evaluation, practitioners could challenge an preliminary six-month provide of buprenorphine, which can be divided throughout a number of prescriptions, totaling six calendar months.
- If the PDMP information will not be accessible however the try to entry it’s documented, practitioners could prescribe solely a seven-day provide of buprenorphine. Practitioners should proceed to verify the PDMP database to challenge subsequent prescriptions. If, after checking, the PDMP stays unavailable and entry makes an attempt are documented, practitioners could prescribe subsequent seven-day provides, as much as the six-month restrict.
Observe-Up Prescriptions
After the preliminary six-month provide, practitioners could challenge extra prescriptions in the event that they both:
- Conduct an in-person medical examination; or
- Meet one of many seven slender exceptions below the Ryan Haight Act (mentioned under) for telemedicine practitioners.
As soon as an in-person medical examination has been performed, the practitioner and affected person are not thought of to be engaged within the apply of telemedicine, and the obligations outlined within the last rule will not apply.
Pharmacist Verification
Earlier than dishing out these prescriptions, pharmacists should confirm the identification of the affected person utilizing one of many following:
- A state government-issued ID;
- A federal government-issued ID; or
- Different acceptable documentation, akin to a paycheck, financial institution or bank card assertion, utility invoice, tax invoice, or voter registration card.
A Temporary Historical past
The principles stem from the Ryan Haight Act, which amended the Managed Substances Act to limit practitioners from prescribing managed substances until the practitioner conducts an in-person examination of the affected person. The Ryan Haight Act (at 21 U.S.C. § 802(54)) outlines seven exceptions below which practitioners could prescribe managed substances by way of telemedicine with out an in-person examination. The fifth exception includes practitioners who’ve obtained the long-awaited particular registration. (Keep tuned for our dialogue on the DEA’s proposed rule establishing a particular registration.) The seventh exception includes different circumstances specified by regulation.
Throughout the COVID-19 Public Well being Emergency (PHE), the DEA issued letters on March 25, 2020, and March 31, 2020, granting short-term exceptions to the Ryan Haight Act and its implementing guidelines that enabled DEA-registered practitioners to prescribe managed substances with out an in-person examination and with a DEA registration in just one state. These telemedicine flexibilities enabled practitioners to prescribe Schedule II-V managed substances by audio-video visits and audio-only visits. Audio-only visits are permitted if the practitioner has the aptitude to make use of audio-video, however the affected person is both unable to make use of video or doesn’t consent to it.
In March 2023, in anticipation of the PHE ending, the DEA issued a proposed rule concerning the growth of telemedicine prescribing of buprenorphine, which acquired important criticism from stakeholders. In response, the DEA rapidly rescinded the proposed rule and prolonged the COVID-era flexibilities in Might 2023. The flexibilities had been subsequently prolonged in October 2023 and November 2024 and are actually set to run out on December 31, 2025. (For extra particulars, see our earlier discussions on the DEA’s proposed guidelines for telemedicine prescribing of managed substances and the first, second, and third short-term guidelines extending COVID-era flexibilities.) Now, in an effort to not lose floor on the growth of telemedicine prescribing of buprenorphine, particularly if the telemedicine flexibilities expire with the incoming Trump administration, the DEA and HHS have revised and finalized their proposed buprenorphine rule.
Evaluating the Proposed and Last Guidelines
The ultimate rule introduces a number of adjustments to the proposed rule, a few of that are described under:
- Provide Limitation: The preliminary 30-day prescription provide limitation by way of audio-only was elevated to a six-month provide.
- In-Individual Medical Analysis: The requirement to have an in-person medical analysis, with three choices for conducting it, to prescribe greater than the preliminary provide of buprenorphine was eliminated.
- Recordkeeping: The detailed recordkeeping necessities for every prescription a practitioner points by a telemedicine encounter, akin to whether or not the encounter was performed by way of audio-video or audio-only, had been eliminated.
- PDMP Evaluate: Though reviewing the PDMP database of the state by which the affected person is positioned on the time of the encounter continues to be required, the specs and recordkeeping necessities for the evaluation had been modified.
The DEA and HHS state that these adjustments are prone to tackle and alleviate most of the considerations raised by commentors, acknowledging that among the beforehand proposed necessities would have positioned undue burdens on each sufferers and practitioners.
Make Your Voice Heard
President Trump’s preliminary spherical of government orders features a regulatory freeze. Underneath the Regulatory Freeze Pending Evaluate Govt Order, government departments, the DEA, and HHS may delay for 60 days from January 20, 2025, the efficient date of the ultimate rule for the aim of reviewing any questions of reality, legislation, and coverage the principles could increase. Throughout this 60-day interval, government departments, the DEA, and HHS may additionally open a remark interval to collect enter from events on these points.
Stakeholders with considerations in regards to the last rule can urge the DEA and the White Home to delay the ultimate rule’s efficient date by way of the next channels:
- E-mail the DEA
- Ship a letter or electronic mail to the White Home
Conclusion
We anticipate that many stakeholders might be dissatisfied with the ultimate rule, significantly with the six-month period for an preliminary provide, which can nonetheless be too quick. If the COVID-era telemedicine prescribing flexibilities expire with out additional extension, the ultimate rule presents safety for prescribing buprenorphine to deal with OUD. Nonetheless, that safety is contingent on establishing a legit particular registration course of, which the DEA has but to suggest or implement. Given the uncertainty surrounding the incoming Trump administration’s priorities and its views on telemedicine prescribing of managed substances, it’s unclear whether or not the ultimate rule might be withdrawn or left as-is. There’s additionally uncertainty about whether or not the telemedicine prescribing flexibilities will expire after 2025. We are going to proceed to observe developments concerning the flexibilities all year long.
For extra data on telemedicine, telehealth, digital care, distant affected person monitoring, digital well being, and different well being improvements, together with the workforce, publications, and consultant expertise, go to Foley’s Telemedicine & Digital Well being Business Crew.
The submit DEA Tightens Buprenorphine Telemedicine Prescribing Guidelines appeared first on Foley & Lardner LLP.